Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 3, 1999, Pages 224-231

  Kinirons, Mark T ^b   O'Shea, Diarmuid ^b   Kim, Richard B ^b   Groopman, John D ^b   Thummel, Kenneth E ^b   Wood, Alastair J J ^b   Wilkinson, Grant R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CARBON 14; CYTOCHROME P450 ISOENZYME; ERYTHROMYCIN; HYDROCORTISONE; MIDAZOLAM;

ADULT; ARTICLE; BODY WEIGHT; BREATH ANALYSIS; CONTROLLED STUDY; DEMETHYLATION; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANTI-ANXIETY AGENTS; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYDROCORTISONE; LINEAR MODELS; MALE; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE; PROTEIN SYNTHESIS INHIBITORS; REFERENCE VALUES;

EID: 0007204117     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70029-9     Document Type: Article

References (46)

1. 1. Maurel P. The CYP3 family. In: Ioannides C, editor. Cytochromes P450: metabolic and toxicological aspects. Boca Raton (FL): CRC Press; 1996. p. 241-70.
2. 2. Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Del Rev 1997;27:99-127.
3. 3. Thummel KE, Wilkinson GR. In vitro and in vivo interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
4. 4. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol Ther 1990;46:377-94.
5. 5. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
6. 6. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P4502E1. Clin Pharmacol Ther 1993;53:643-50.
7. 7. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994;47:1503-8.
8. 8. Kim RB, O'Shea D, Wilkinson GR. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995;57:645-55.
9. 9. Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA. Use of chlorzoxazone as an in vivo probe of cytochrome P4502E1: choice of dose and phenotypic trait. J Clin Pharmacol 1998;38:82-9.
10. 10. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
11. 11. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
12. 12. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton ST. Regioselective biotransformation of midazolam by members of the human cytochrome P4503A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-53.
13. 13. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P450 3A probe; I: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
14. 14. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, et al. Use of midazolam as a human cytochrome P450 3A probe; II: characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-66.
15. 15. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
16. 16. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.
17. 17. Krivoruk Y, Kinirons MT, Wood AJJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994;56:608-14.
18. 18. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJJ. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996;59:47-51.
19. 19. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P450: studies in rats and patients. J Clin Invest 1989;83: 688-97.
20. 20. Austin KL, Mather LE, Philpot CR, McDonald PJ. Inter-subject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980;10:273-9.
21. 21. Hunt CM, Westerkam WR, Stave GM. Effects of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.
22. 22. Schuetz EG, Yasuda K, Arimori K, Schuetz JD. Human MDRI and mouse mdrIa P-glycoprotein after the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch Biochem Biophys 1998;350:340-7.
23. 23. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between inhibitors and substrates of human CYP3A and P-glycoprotein. Pharm Res 1999;16:408-14.
24. 24. Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995;275:1011-8.
25. 25. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990;38:207-13.
26. 26. Wrighton SA, Ring BJ, Watkins PB, VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989;36:97-105.
27. 27. Lown KE, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-55.
28. 28. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996:60: 14-24.
29. 29. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-7.
30. 30. Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam: a review of its pharmacological properties and therapeutic use. Drugs 1984;28:519-43.
31. 31. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al. The erythromycin breath test predicts clearance of midazolam. Clin Pharmacol Ther 1995;57:16-24.
32. 32. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994:33:6450-5.
33. 33. Ueng YF, Kuwabara T, Chun YJ, Guengerich FP. Cooperativity in oxidations catalyzed by cytochrome P4503A. Biochemistry 1997;36;370-81.
34. 34. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, et al. Evaluation of atypical cytochrome P450 kinetics and two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998;37; 4137-47.
35. 35. Koley AP, Robinson RC, Markowitz A, Friedman FK. Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P4503A4. Biochem Pharmacol 1997;53:455-60.
36. 36. Chelvan P, Hamilton-Miller JMT, Brumfitt W. Biliary excretion of erythromycin after parenteral administration. Br J Clin Pharmacol 1979;8:233-5.
37. 37. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-34.
38. 38. Park BK. Assessment of urinary 6β-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br J Clin Pharmacol 1981;12:97-102.
39. 39. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic P450IIIA induction. Br J Clin Pharmacol 1989;28:373-87.
40. 40. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, et al. Comparison of urinary 6β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992;52:265-73.
41. 41. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992;51:229-38.
42. 42. Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992;51:18-23.
43. 43. Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, et al. Expression of cytochrome P4053A in amphibian rat and human kidney. Arch Biochem Biophys 1992;294:206-14.
44. 44. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kirokan N, et al. Human P-glycoprotein transports cortisol, aldosterone and dexamethasone but not progesterone. J Biol Chem 1992;267:24248-52.
45. 45. Cheng CL, Smith E, Carver PL, Cox SR, Watkins PB, Blake DS, et al. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther 1997;61:531-43.
46. 46. Jamis-Dow CA, Pearl ML, Watkins PB, Blake DS, Klecker RW, Collins JM. Predicting drug interactions in vivo from experiments in vitro. Am J Clin Oncol 1997;20: 592-99.